GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on April 4, 2025, reporting events occurring on March 31, 2025. The Company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC. As of July 1, 2024, the Company operates as a fully remote entity without a principal executive office.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial value disclosed relates to a specific transaction:
- Transaction Value: $846,562.50 (aggregate exercise price of a pre-funded warrant).
- Consideration: Services rendered by Cytovance Biologics, Inc.
Material Changes
On March 31, 2025, the Company issued a pre-funded warrant to Cytovance Biologics, Inc. for the purchase of up to 326,251 shares of Common Stock. This issuance was made in partial consideration for services provided. The warrant is immediately exercisable at a nominal price of $0.0001 per share, with the aggregate value of $846,562.50 pre-funded via services. The securities were sold without registration under the Securities Act of 1933, relying on Section 4(a)(2) exemptions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are detailed beyond the standard disclosure regarding the unregistered sale of equity securities.
Investor Verification Checklist
- Verify the terms of the Pre-funded Common Stock Purchase Warrant filed as Exhibit 4.1.
- Confirm the nature and valuation of services provided by Cytovance Biologics, Inc. totaling $846,562.50.
- Review the impact of the 326,251 potential new shares on existing shareholder dilution.
- Check for any subsequent filings regarding the exercise of the warrant or changes in beneficial ownership.